Literature DB >> 15372156

[Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].

K Rohrmann1, J Schleypen, C Adam, A Hofstetter, M Siebels.   

Abstract

Therapy of metastasized renal cell carcinoma is based on systemic immunotherapeutic strategies, if surgical resection is not possible. The costs of inhalative Interleukin-2 therapy in case of pulmonary metastases as off-label-use are not accepted by compulsory health insurance yet.We report on a female patient with pulmonary metastasized renal cell carcinoma who had tumor progression after immunochemotherapy that followed complete response after inhalative therapy with Interleukin-2.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15372156     DOI： 10.1007/s00120-004-0669-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  12 in total

1.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

Authors:  S Negrier; B Escudier; C Lasset; J Y Douillard; J Savary; C Chevreau; A Ravaud; A Mercatello; J Peny; M Mousseau; T Philip; T Tursz
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

2.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

Authors:  B Escudier; C Chevreau; C Lasset; J Y Douillard; A Ravaud; M Fabbro; A Caty; J F Rossi; P Viens; J P Bergerat; J Savary; S Négrier
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

3.  Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).

Authors:  E Huland; H Heinzer; H Huland
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

4.  [Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil].

Authors:  G Hofmockel; M Theiss; A Gruss; W Langer; H Frohmüller
Journal:  Urologe A       Date:  1997-01       Impact factor: 0.639

5.  Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.

Authors:  Jens Atzpodien; Reinhard Hoffmann; Marcus Franzke; Christian Stief; Thomas Wandert; Martina Reitz
Journal:  Cancer       Date:  2002-09-01       Impact factor: 6.860

6.  Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.

Authors:  Julia S Schleypen; Marion Von Geldern; Elisabeth H Weiss; Nicole Kotzias; Karl Rohrmann; Dolores J Schendel; Christine S Falk; Heike Pohla
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

7.  [Immunotherapy of metastatic renal cell carcinoma in Germany. An assessment of the current status].

Authors:  E Huland; H Heinzer; S Timm; M Alamian; H Huland
Journal:  Urologe A       Date:  2002-05       Impact factor: 0.639

8.  Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.

Authors:  Allan J Pantuck; Amnon Zisman; Fredrick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

Review 9.  Cytokine combinations in immunotherapy for solid tumors: a review.

Authors:  K M Heaton; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

10.  Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.

Authors:  J Lorenz; K Wilhelm; M Kessler; C Peschel; U Schwulera; R Lissner; W G Struff; E Huland; C Huber; W E Aulitzky
Journal:  Clin Cancer Res       Date:  1996-07       Impact factor: 12.531
View more
  1 in total

Review 1.  [Therapy strategies for advanced renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; C Adam; C G Stief
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.